Tonsillectomy delays progression of advanced IgA nephropathy to end-stage kidney disease

Renal Failure

Volumn 34, Issue 4, 2012, Pages 448-453

  Komatsu, Hiroyuki ^a   Fujimoto, Shouichi ^a   Kikuchi, Masao ^a,b   Sato, Yuji ^a,b   Kitamura, Kazuo ^a,b  

^a UNIVERSITY OF MIYAZAKI HOSPITAL   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

End stage kidney disease; Glomerulonephritis; IgA nephropathy; Renal outcome; Tonsillectomy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN A; STEROID;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEMATURIA; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NEPHRITIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; RISK FACTOR; STEROID THERAPY; SURVIVAL; TONSILLECTOMY;

ADULT; BIOPSY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS, IGA; HUMANS; INCIDENCE; JAPAN; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TONSILLECTOMY;

EID: 84859569594     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2011.653775     Document Type: Article

References (35)

1. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;64:709-727. (Pubitemid 18047151)
2. Julian BA, Waldo FB, Rifai A, Mestecky J. IgA nephropathy, the most common glomerulonephritis worldwide: A neglected disease in the United States? Am J Med. 1988;84:129-132.
3. Sugiyama H, Yokoyama H, Sato H, et al. Committee for Standardization of Renal Pathological Diagnosis and Working Group for Renal Biopsy Database, Japanese Society of Nephrology, Tokyo, Japan. Japan Renal Biopsy Registry: The first nationwide, web-based, and prospective registry system of renal biopsies in Japan. Clin Exp Nephrol. 2011;15:493-503.
4. Floege J. The pathogenesis of IgA nephropathy: What is new and how does it change therapeutic approaches? Am J Kidney Dis. 2011;58:992-1004.
5. Cheng J, Zhang X, Zhang W, He Q, Tao X, Chen J. Efficacy and safety of glucocorticoids therapy for IgA nephropathy: A meta-analysis of randomized controlled trials. Am J Nephrol. 2009;30:315-322.
6. Zhou YH, Tang LG, Guo SL, et al. Steroids in the treatment of IgA nephropathy to the improvement of renal survival: A systematic review and meta-analysis. PLoS One. 2011;6:e18788.
7. Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E. Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol. 2003;14: 1578-1583. (Pubitemid 36687059)
8. Coppo R, Peruzzi L, Amore A, et al. IgACE: A placebocontrolled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol. 2007;18: 1880-1888. (Pubitemid 46870324)
9. Xie Y, Nishi S, Ueno M, et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int. 2003;63:1861-1867. (Pubitemid 36513334)
10. Akagi H, Kosaka M, Hattori K, et al. Long-term results of tonsillectomy as a treatment for IgA nephropathy. Acta Otolaryngol Suppl. 2004;Suppl. 555:38-42. (Pubitemid 40023703)
11. Komatsu H, Fujimoto S, Hara S, et al. Multivariate analysis of prognostic factors and effect of treatment in patients with IgA nephropathy. Ren Fail. 2005;27:45-52. (Pubitemid 40180107)
12. Chen Y, Tang Z,Wang Q, et al. Long-term efficacy of tonsillectomy in Chinese patients with IgA nephropathy. Am J Nephrol. 2007;27:170-175. (Pubitemid 46588183)
13. Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol. 1999;51:147-152. (Pubitemid 29116416)
14. Piccoli A, Codognotto M, Tabbi MG, Favaro E, Rossi B. Influence of tonsillectomy on the progression of mesangioproliferative glomerulonephritis. Nephrol Dial Transplant. 2010;25:2583-2589.
15. Komatsu H, Fujimoto S, Sato Y, et al. "Point of no return (PNR)" in progressive IgA nephropathy: Significance of blood pressure and proteinuria management up to PNR. J Nephrol. 2005;18:690-695. (Pubitemid 43085435)
16. Churg J, Bernstein J, Glassock RJ. Renal Disease: Classification and Atlas of Glomerular Disease. 2nd ed., Tokyo: Igaku-Shoin; 1995:4-20.
17. Koyama A, Igarashi M, KobayashiM, et al. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Am J Kidney Dis. 1997;29:526-532. (Pubitemid 27155272)
18. Imai E, Horio M, Nitta K, et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol. 2007;11:41-50. (Pubitemid 46474965)
19. Tomino Y, Sakai H. Clinical guidelines for immunoglobulin A (IgA) nephropathy in Japan, second version. Clin Exp Nephrol. 2003;7:93-97. (Pubitemid 36898685)
20. Bene MC, Hurault De Ligny B, Kessler M, Faure GC. Confirmation of tonsillar anomalies in IgA nephropathy: A multicenter study. Nephron. 1991;58:425-428.
21. Bene MC, Hurault Ligny B, Kessler M, Foliguet B, Faure GC. Tonsils in IgA nephropathy. Contrib Nephrol. 1993;104: 153-161.
22. Barratt J, Smith AC, Feehally J. The pathogenic role of IgA1 O-linked glycosylation in the pathogenesis of IgA nephropathy. Nephrology (Carlton). 2007;12:275-284. (Pubitemid 46718210)
23. Tanaka M, Seki G, Someya T, Nagata M, Fujita T. Aberrantly glycosylated IgA1 as a factor in the pathogenesis of IgA nephropathy. Clin Dev Immunol. 2011;2011: 470803.
24. Novak J, Moldoveanu Z, Julian BA, et al. Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: Role of mucosal immune system. Adv Otorhinolaryngol. 2011;72:60-63.
25. Itoh A, Iwase H, Takatani T, et al. Tonsillar IgA1 as a possible source of hypoglycosylated IgA1 in the serum of IgA nephropathy patients. Nephrol Dial Transplant. 2003;18: 1108-1114. (Pubitemid 36722511)
26. Suzuki Y, Tomino Y. Potential immunopathogenic role of the mucosa-bone marrow axis in IgA nephropathy: Insights from animal models. Semin Nephrol. 2008;28:66-77.
27. van den Wall Bake AW, Daha MR, Evers-Schouten J, van Es LA. Serum IgA and the production of IgA by peripheral blood and bone marrow lymphocytes in patients with primary IgA nephropathy: Evidence for the bone marrow as the source of mesangial IgA. Am J Kidney Dis. 1988;12: 410-414.
28. van den Wall Bake AW, Daha MR, Radl J, et al. The bone marrow as production site of the IgA deposited in the kidneys of patients with IgA nephropathy. Clin Exp Immunol. 1988;72:321-325.
29. Komatsu H, Fujimoto S, Hara S, et al. Recent therapeutic strategies improve renal outcome in patients with IgA nephropathy. Am J Nephrol. 2009;30:19-25.
30. Wang Y, Chen J, Wang Y, Chen Y, Wang L, Lv Y. A metaanalysis of the clinical remission rate and long-term efficacy of tonsillectomy in patients with IgA nephropathy. Nephrol Dial Transplant. 2011;26:1923-1931.
31. Kennoki T, Ishida H, Yamaguchi Y, Tanabe K. Proteinuriareducing effects of tonsillectomy alone in IgA nephropathy recurring after kidney transplantation. Transplantation. 2009;88:935-941.
32. Ushigome H, Suzuki T, Fujiki M, et al. Efficacy of tonsillectomy for patients with recurrence of IgA nephropathy after kidney transplantation. Clin Transplant. 2009;23(Suppl. 20):17-22.
33. Tsuchiya T, Ito S, Yamaguchi Y, Moriyama Y, Ehara H, Deguchi T. Tonsillectomy and steroid pulse therapy for recurrent IgA nephropathy in renal allograft. Clin Nephrol. 2010;73:68-71.
34. Hotta O, Miyazaki M, Furuta T, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736-743.
35. Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Kitamura K. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: A controlled study. Clin J Am Soc Nephrol. 2008;3:1301-1307.